Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC) – Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single Ascending Dose (SAD)...

Two Discovery Senior Living Team Members Appointed to Argentum's 2022 LEAD Program Cohort BONITA SPRINGS, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Discovery Senior Living ("Discovery") has announced that team members Christian Steil and Savannah Rogers will be part of the second-ever...

Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD – Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16) – All...